Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI   US84763A1088

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/16/2015 01/20/2015 01/21/2015 01/22/2015 01/23/2015 Date
6.76(c) 6.79(c) 6.66(c) 6.79(c) 6.77(c) Last
602 824 733 160 478 565 750 283 615 424 Volume
-0.59% +0.44% -1.91% +1.95% -0.29% Change
More quotes
Company
Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations, with a primary focus in hematology and oncology.It operates through one segment: acquiring, developing and commercializing prescription drug products.The company markets two... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 185 M
EBIT 2014 -36,0 M
Net income 2014 -48,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 208 M
EBIT 2015 -7,78 M
Net income 2015 -15,9 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 2,41x
Capi. / Sales 2015 2,15x
Capitalization 445 M
More Financials
Latest news on SPECTRUM PHARMACEUTICALS,
01/07 SPECTRUM PHARMACEUTICALS : Technical Scrutiny on Biotech Stocks - Galena Biophar..
01/05 LIGAND PHARMACEUTICALS : Partner Spectrum Pharmaceuticals Submits New Drug Appli..
2014 LIGAND PHARMACEUTICALS : Partner Spectrum Pharmaceuticals Announces Submission o..
2014 SPECTRUM PHARMACEUTICALS : Files a New Drug Application with the FDA for Captiso..
2014 SPECTRUM PHARMACEUTICALS : Insider-trading case: grewal couple pay $90,960 as di..
2014 SPECTRUM PHARMACEUTICALS : Highlights 11 Abstracts at the 56th Annual Meeting of..
2014 ONXEO : Gets Milestone Payment on Beleodaq
2014 ONXEO : Secures Milestone Payment on Beleodaq
More news
Sector news Biotechnology & Medical Research - NEC
01/23 INCYTE : Earns $25 Million Milestone as Jakavi® (ruxolitinib) Recommended for Ap..
01/23 MEDIVATION : Astellas -enzalutamide phase 2 terrain trial demonstrated statistic..
01/22 QUINTILES TRANSNATIONAL : Investigator Initiated Trials is Topic of New Handbook..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF